21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

      American journal of respiratory and critical care medicine
      Anti-Asthmatic Agents, therapeutic use, Anti-Bacterial Agents, Anti-Inflammatory Agents, Child, Cystic Fibrosis, drug therapy, Deoxyribonuclease I, Humans

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.

          Related collections

          Author and article information

          Journal
          17761616
          10.1164/rccm.200705-664OC

          Chemistry
          Anti-Asthmatic Agents,therapeutic use,Anti-Bacterial Agents,Anti-Inflammatory Agents,Child,Cystic Fibrosis,drug therapy,Deoxyribonuclease I,Humans

          Comments

          Comment on this article